

Notice from the Executive Officer: Funding of Inflectra (infliximab) Under the Ontario Drug Benefit Program

March 11, 2016

Effective **February 25, 2016**, the Ontario Public Drug Programs (OPDP) began funding Inflectra (infliximab) as a Limited Use (LU) benefit for eligible ODB recipients for the following indications:

- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Plaque Psoriasis

The LU criteria are posted in the eFormulary which can found on the ministry's website at:

http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_eformulary.aspx

The funding of Remicade (infliximab) remains unchanged and recipients with existing approvals under the Exceptional Access Program can continue to access the Remicade (infliximab) product.

To further inform healthcare providers and patients, we have also included a Frequently Asked Questions (FAQs) document for reference purposes.

Additional Information:

For pharmacies:

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other Health Care Providers and the Public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282